Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Anti-Aging supplement TA-65 targets blood vessel health in new study

NCT ID NCT05598359

Disease control Sponsor: Medical College of Wisconsin Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether TA-65, a dietary supplement that activates telomerase, can improve small blood vessel function in healthy older adults and people with coronary artery disease. Researchers will measure blood vessel responses and blood pressure in 180 participants. The goal is to see if TA-65 can help counteract age-related blood vessel decline.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 180 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy Adults 18 - 35 and 65+ years of age * Subjects with clinical diagnosis of CAD Exclusion criteria will include: * 36-64 years of age without clinical diagnosis of CAD * Self-reported habitual vigorous exercise (\>20 min, 3 times per week, 1 yr) * Major Adverse Cardiovascular Event (MACE) in the last year (heart attack, stroke) * Heart Failure * Renal Impairment * \>3 Pre-existing Cardiovascular Risk Factors (healthy groups only) * Type 1 or type 2 diabetes * Uncontrolled hypertension * Current tobacco use or within last 6 months * BMI \> 35 * Hyperlipidemia * Hypercholesterolemia * Use of anti-coagulant drugs * Use of anti-platelet drugs * Erectile dysfunction medication in the past 6 months * Use of topical/non-topical steroids in last 6 months * Hormone replacement therapy (Post-Menopause or Gender Reassignment) * History of retinopathy * Documented neuromuscular disorders * Porphyria Cutanea Tarda (blistering of skin to sun; photosensitivity) * Pregnancy (young female subjects) * Allergy to lidocaine * Current diagnosis of cancer with or without active anti-cancer treatment (pharmaceuticals) or treatment within last 12 months * Active COVID-19 or within the past 3 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aging are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder vascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aging Telomere shortening Vascular diseases

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.